Teva Pharmaceuticals

Alvotech, Stelara, Johnson & Johnson, Humira, Teva Pharmaceuticals, Reykjavik

Teva and Alvotech face FDA rejection for Stelara biosimilar after Humira setbacks

Anika Sharma

Ongoing issues at the Alvotech manufacturing facility in Reykjavik have led to yet another FDA rejection, this time affecting the ...

Lilly secures Emgality’s future after judge invalidates Teva’s patents

Lilly secures Emgality’s future after judge invalidates Teva’s patents

Anika Sharma

A federal judge in Massachusetts has ruled in favor of Eli Lilly, overturning a $176.5 million jury verdict issued in ...

Teva Pharmaceuticals, Alkermes, Vivitrol, Patent settlement, Generics

Teva Wins License to Launch Generic Vivitrol in 2027 After Patent Settlement with Alkermes

Anika Sharma

Teva Pharmaceuticals has secured a pivotal victory in a patent dispute settlement with Alkermes, the manufacturer of Vivitrol. This settlement ...

Teva Pharmaceuticals, Glenmark, Patent settlement, Generics, US Department of Justice

Teva and Glenmark Agree to $255M Settlement with DOJ in Price-Fixing Case

Anika Sharma

Teva and Glenmark Pharmaceuticals, implicated in a price-fixing scheme, are facing substantial penalties and divestiture mandates after reaching a deferred ...

Teva Faces Delay in $1.2 Billion Kickbacks Case

Teva Gains Trial Postponement for Unique Appeal Strategy in Copaxone Case Against US Government

Anika Sharma

After an enduring three-year legal battle against allegations by the US government, Teva Pharmaceuticals has managed to secure a delay ...

Teva’s Recovery Boosted by Austedo and Uzedy

With Austedo running and the Uzedy launch underway, Teva is beginning to show indications of improvement

SG Tylor

With a fresh growth strategy in place and two successful recent launches, Teva seems to be stepping into a new ...

Teva’s $200M Deal to End Price-Fixing Probe

Teva sets aside $200 million in ‘advanced’ settlement negotiations to end the US price-fixing investigation

SG Tylor

Teva, a pharmaceutical company facing a price-fixing indictment by the U.S. Department of Justice (DOJ), is taking steps to resolve ...

Teva Settles Opioid Litigation for $4.25B, Eyes Growth by 2027

Teva Aims for Growth by 2027 After $4.25B Opioid Settlement

SG Tylor

Teva Pharmaceutical is shifting its focus back to its core businesses in generics and biosimilars, seeing promising opportunities in both ...

Teva Fights Kickbacks Verdict to Avoid $10B Trial Loss

Teva Seeks Appeal in Kickbacks Case Amid $10 Billion Trial Risk

SG Tylor

Teva has been grappling with opioid litigation for several years, culminating in a multibillion-dollar settlement last year. However, the company ...

Teva Snags Angus Grant from BeiGene as Biz Dev Chief

Teva’s CEO Francis Recruits Angus Grant, Former BeiGene Business Development Head

SG Tylor

Teva Pharmaceutical Industries Ltd., the world’s largest maker of generic drugs, has announced the appointment of a new executive to ...

Exelixis and Teva Settle Cabometyx Patent Dispute, Allow Generic in 2031

Cabometyx patent battle is resolved by Exelixis and Teva with a 2031 generic license

SG Tylor

Source – Exelixis Exelixis, the company behind the successful cancer drug Cabometyx, has been actively defending its intellectual property. In ...